{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T01:56:50Z","timestamp":1777341410527,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.ejca.2012.01.036","type":"journal-article","created":{"date-parts":[[2012,2,28]],"date-time":"2012-02-28T10:59:22Z","timestamp":1330426762000},"page":"974-981","source":"Crossref","is-referenced-by-count":43,"title":["Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: A cohort study"],"prefix":"10.1016","volume":"48","author":[{"given":"Sandra","family":"Feldt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Sch\u00fcssel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate","family":"Quinzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Franzmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sittah","family":"Czeche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf-Dieter","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2012.01.036_b0005","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrclinonc.2009.4","article-title":"Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy","volume":"6","author":"Torino","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2012.01.036_b0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11912-011-0154-3","article-title":"Development of second-generation VEGFR tyrosine kinase inhibitors: current status","volume":"13","author":"Bhargava","year":"2011","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ejca.2012.01.036_b0015","first-page":"CD001425","article-title":"Immunotherapy for advanced renal cell cancer","volume":"1","author":"Coppin","year":"2005","journal-title":"Cochrane Database"},{"key":"10.1016\/j.ejca.2012.01.036_b0020","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2012.01.036_b0025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2012.01.036_b0030","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00761-009-1760-7","article-title":"\u201cTargeted therapy\u201d bei metastasiertem Nierenzellkarzinom","volume":"16","author":"Schenck","year":"2010","journal-title":"Onkologe"},{"key":"10.1016\/j.ejca.2012.01.036_b0035","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.eururo.2010.06.032","article-title":"EAU guidelines on renal cell carcinoma: the 2010 update","volume":"58","author":"Ljungberg","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2012.01.036_b0040","unstructured":"EMA\u2013European Public Assessment Report \u2013 Product Information. SUTENT\u00ae sunitinib. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000687\/WC500057737.pdf. London, November 18, 2009 [accessed 1.11.2011]."},{"key":"10.1016\/j.ejca.2012.01.036_b0045","unstructured":"EMA\u2013European Public Assessment Report \u2013 Product Information. NEXAVAR\u00ae sorafenib. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000690\/WC500027704.pdf. London, December 21, 2009 [accessed 1.11.2011]."},{"key":"10.1016\/j.ejca.2012.01.036_b0050","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(09)70222-0","article-title":"Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"10","author":"Je","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2012.01.036_b0055","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","article-title":"Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Wu","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2012.01.036_b0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1471-2407-11-105","article-title":"Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy","volume":"11","author":"Porta","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2012.01.036_b0065","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.eururo.2011.01.002","article-title":"Toxicities of targeted therapy and their management in kidney cancer","volume":"4","author":"Di Lorenzo","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2012.01.036_b0070","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/thy.2006.0308","article-title":"Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity","volume":"17","author":"Wong","year":"2007","journal-title":"Thyroid"},{"key":"10.1016\/j.ejca.2012.01.036_b0075","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1470-2045(07)70016-5","article-title":"Fatigue with sunitinib-induced hypothyroidism","volume":"8","author":"Senior","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2012.01.036_b0080","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/sj.bjc.6604497","article-title":"The clinical implications of sunitinib induced hypothyroidism: a prospective evaluation","volume":"99","author":"Wolter","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2012.01.036_b0085","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-145-9-200611070-00008","article-title":"Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors","volume":"145","author":"Desai","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejca.2012.01.036_b0090","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jnci\/djk008","article-title":"Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"99","author":"Rini","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2012.01.036_b0095","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/annonc\/mdm483","article-title":"Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib","volume":"19","author":"Tamaskar","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2012.01.036_b0100","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.urolonc.2009.08.011","article-title":"Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation","volume":"5","author":"Miyake","year":"2010","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ejca.2012.01.036_b0105","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1210\/jc.2011-1172","article-title":"Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression","volume":"10","author":"Kappers","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejca.2012.01.036_b0110","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.bjc.6606029","article-title":"The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma","volume":"2","author":"Shinohara","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2012.01.036_b0115","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1210\/jc.2007-0586","article-title":"A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake","volume":"92","author":"Mannavola","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejca.2012.01.036_b0120","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/jnci\/djm006","article-title":"Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"99","author":"Feldmann","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2012.01.036_b0125","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with the tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2012.01.036_b0130","unstructured":"FDA 2006a. Center for Drug Evaluation and Research, SUTENT\u00ae approval package for: Application Number NDA 21-938 (GIST), NDA 21-968 (MRCCD), Medical Review(s), January 26, 2006. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/021938s000_021968s000_Stutent.cfm [accessed 1.11.2011]."},{"key":"10.1016\/j.ejca.2012.01.036_b0135","unstructured":"FDA 2006b. Center for Drug Evaluation and Research, Drugs@FDA: SUTENT\u00ae label information, January 26, 2006. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/021938_S000_Sutent_Prntlbl.pdf [accessed 16.2.2012]."},{"key":"10.1016\/j.ejca.2012.01.036_b0140","first-page":"1","article-title":"Hypothyroidism: a frequent adverse drug reaction under treatment with sunitinib","volume":"107","year":"2007","journal-title":"Dtsch Arztebl"},{"key":"10.1016\/j.ejca.2012.01.036_b0145","doi-asserted-by":"crossref","first-page":"457","DOI":"10.4158\/1934-2403-8.6.457","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism","volume":"8","author":"Baskin","year":"2002","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ejca.2012.01.036_b0150","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jama.291.2.228","article-title":"Subclinical thyroid disease: scientific review and guidelines for diagnosis and management","volume":"291","author":"Surks","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2012.01.036_b0155","unstructured":"EMA - European Public Assessment Report \u2013 Scientific Discussion. SUTENT\u00ae sunitinib. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000687\/WC500057733.pdf. London, January 10, 2007 [accessed 16.2.2012]."},{"key":"10.1016\/j.ejca.2012.01.036_b0160","unstructured":"EMA - European Public Assessment Report \u2013 Scientific Discussion. NEXAVAR\u00ae sorafenib. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000690\/WC500027707.pdf. London, March 4, 2007 [accessed 16.2.2012]."},{"key":"10.1016\/j.ejca.2012.01.036_b0165","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1507\/endocrj.K10E-130","article-title":"Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma","volume":"10","author":"Sato","year":"2010","journal-title":"Endocr J"},{"key":"10.1016\/j.ejca.2012.01.036_b0170","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1210\/jc.2009-2507","article-title":"Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination","volume":"95","author":"Abdulrahman","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejca.2012.01.036_b0175","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1677\/joe.0.1660475","article-title":"Angiogenesis in the thyroid gland","volume":"166","author":"Ramsden","year":"2000","journal-title":"J Endocrinol"},{"key":"10.1016\/j.ejca.2012.01.036_b0180","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1200\/JCO.2010.31.9624","article-title":"Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials","volume":"29","author":"Seruga","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.01.036_b0185","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/nrurol.2010.191","article-title":"Kidney cancer: does hypothyroidism predict clinical outcome?","volume":"1","author":"Rini","year":"2011","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ejca.2012.01.036_b0190","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000262450","article-title":"Antiangiogenic drugs in oncology: a focus on drug safety and the elderly \u2013 a mini-review","volume":"3","author":"Boehm","year":"2010","journal-title":"Gerontology"},{"key":"10.1016\/j.ejca.2012.01.036_b0195","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/COC.0b013e3181a650a6","article-title":"Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma","volume":"3","author":"La Vine","year":"2010","journal-title":"Am J Clin Oncol"},{"issue":"Suppl.1","key":"10.1016\/j.ejca.2012.01.036_b0205","doi-asserted-by":"crossref","first-page":"S699","DOI":"10.1007\/s12032-010-9757-z","article-title":"Sunitinib-induced severe hypothyroidism with cardiac compromise","volume":"28","author":"Collinson","year":"2011","journal-title":"Med Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912001013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912001013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T17:49:01Z","timestamp":1640972941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804912001013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0959804912001013"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2012.01.036","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}